53018DE1-9557-4181-A0F2-5200013F1CEA
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 34.88830486202365
- age_years
- 60
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.621
- E2F_TARGETS+0.607
- INTERFERON_GAMMA_RESPONSE+0.577
- TNFA_SIGNALING_VIA_NFKB+0.570
- G2M_CHECKPOINT+0.562
- IL6_JAK_STAT3_SIGNALING+0.554
- INFLAMMATORY_RESPONSE+0.503
- ALLOGRAFT_REJECTION+0.495
- ANGIOGENESIS+0.490
- MYC_TARGETS_V1+0.490
Top 10 suppressed
- KRAS_SIGNALING_DN-0.275
- HEDGEHOG_SIGNALING-0.173
- MYOGENESIS-0.142
- SPERMATOGENESIS-0.141
- BILE_ACID_METABOLISM-0.038
- PANCREAS_BETA_CELLS-0.021
- OXIDATIVE_PHOSPHORYLATION-0.010
- WNT_BETA_CATENIN_SIGNALING+0.029
- UV_RESPONSE_DN+0.048
- ESTROGEN_RESPONSE_EARLY+0.055
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 113D7756-712E-4EB4-9993-BBAF3C41AFEF | — | — | 0.966 |
| 2 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.965 |
| 3 | 2B311620-94F3-4B53-B66A-81AC0A32453B | — | — | 0.965 |
| 4 | 3D3C3AAA-2C7A-43C6-8137-73A6E0896FAC | — | — | 0.963 |
| 5 | SRR934874 | — | — | 0.963 |
| 6 | 4B93A447-E626-4040-9BA0-1EEAB3764C6B | — | — | 0.962 |
| 7 | 7E198F8E-BBAA-419D-8986-359C109FBE74 | — | — | 0.961 |
| 8 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.959 |
| 9 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.958 |
| 10 | SRR934965 | — | — | 0.958 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.621 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.607 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.577 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.570 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.562 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.554 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.503 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.495 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.476 | Inavolisib | — uncovered |
| APOPTOSIS | 0.461 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| HYPOXIA | 0.455 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.455 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.447 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.443 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.411 | Idelalisib | — uncovered |
| COMPLEMENT | 0.409 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.404 | Idelalisib | — uncovered |